Resmed (RSMDF) Operating Expenses (2009 - 2026)

Resmed (RSMDF) has reported Operating Expenses for 18 consecutive years, with $412.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 12.85% year-over-year to $412.5 million; the trailing twelve-month figure through Jun 2026 stood at $1.6 billion (up 14.27% YoY), and the FY2026 full-year result was $1.6 billion, up 14.27% from the prior year.
• Operating Expenses advanced to $412.5 million in Q2 2026 per RSMDF's latest filing, from $391.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $412.5 million in Q2 2026 and bottomed at $256.9 million in Q1 2022.
• Historically, Operating Expenses has averaged $334.3 million across 5 years, with a median of $334.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses gained 28.08% in 2023, then retreated 10.17% in 2024.
• Over 5 years, Operating Expenses stood at $299.5 million in 2022, then advanced by 24.14% to $371.8 million in 2023, then retreated by 10.17% to $334.0 million in 2024, then rose by 15.88% to $387.1 million in 2025, then gained by 6.57% to $412.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $412.5 million, $391.2 million, and $387.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.